SCHEMBL1709595

SCHEMBL1709595

COc1ccc(OC(C(=O)Nc2ccc(Cl)cn2)c2ccc(Cl)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 1/20 0.56
ALDH1A1 P00352 4/20 0.52
RAB9A P51151 6/20 0.51
NPC1 O15118 5/20 0.51
TSHR P16473 2/20 0.51
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
MAPT P10636 2/20 0.50
LMNA P02545 3/20 0.49
KDM4E B2RXH2 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
MAPK1 P28482 1/20 0.49
PTK2 Q05397 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
CASP3 P42574 2/20 0.48
SENP8 Q96LD8 2/20 0.48
SENP7 Q9BQF6 2/20 0.48
SENP6 Q9GZR1 2/20 0.48
NFKB1 P19838 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL934457 0.99 GCK (0.55) GCKALDH1A1RAB9ANPC1TSHR
SCHEMBL1709567 0.94 GCK (0.61) GCKALDH1A1RAB9ANPC1TSHR
Hydrochloric Acid SCHEMBL933546 0.92 GCK (0.60) GCKALDH1A1RAB9ANPC1TSHR
SCHEMBL12945247 0.92 GCK (0.53) GCKALDH1A1RAB9ANPC1TSHR
SCHEMBL1709591 0.88 GCK (0.56) GCKALDH1A1RAB9ANPC1TSHR
Hydrochloric Acid SCHEMBL934456 0.87 GCK (0.55) GCKALDH1A1RAB9ANPC1TSHR
SCHEMBL1709592 0.85 TDP1 (0.58) GCKALDH1A1RAB9ANPC1TSHR
SCHEMBL1709534 0.84 FFAR2 (0.65) GCKALDH1A1RAB9ANPC1TSHR
SCHEMBL1709544 0.84 GCK (0.57) GCKRAB9ANPC1TSHRMEN1
Hydrochloric Acid SCHEMBL993258 0.84 TDP1 (0.57) GCKALDH1A1RAB9ANPC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS ALLERGAN, INC. (US) 2012-04-12 US disclosed
WO-2011008475-A1 OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES ALLERGAN, INC. (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS S1PR3, S1PR5, S1PR1 GCK 2816/4885ALDH1A1 3344/4885RAB9A 2924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.